1887

Abstract

The lyssaviruses are an important group of viruses that cause a fatal encephalitis termed rabies. The prototypic lyssavirus, rabies virus, is predicted to cause more than 60 000 human fatalities annually. The burden of disease for the other lyssaviruses is undefined. The original reports for the recently described highly divergent Lleida bat lyssavirus were based on the detection of virus sequence alone. The successful isolation of live Lleida bat lyssavirus from the carcass of the original bat and in vitro characterization of this novel lyssavirus are described here. In addition, the ability of a human rabies vaccine to confer protective immunity following challenge with this divergent lyssavirus was assessed. Two different doses of Lleida bat lyssavirus were used to challenge vaccinated or naïve mice: a high dose of 100 focus-forming units (f.f.u.) 30 µl and a 100-fold dilution of this dose, 1 f.f.u. 30 µl. Although all naïve control mice succumbed to the 100 f.f.u. 30 µl challenge, 42 % (n=5/12) of those infected intracerebrally with 1 f.f.u. 30 µl survived the challenge. In the high-challenge-dose group, 42 % of the vaccinated mice survived the challenge (n=5/12), whilst at the lower challenge dose, 33 % (n=4/12) survived to the end of the experiment. Interestingly, a high proportion of mice demonstrated a measurable virus-neutralizing antibody response, demonstrating that neutralizing antibody titres do not necessarily correlate with the outcome of infection via the intracerebral route. Assessing the ability of existing rabies vaccines to protect against novel divergent lyssaviruses is important for the development of future public health strategies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001068
2018-05-05
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/12/1590.html?itemId=/content/journal/jgv/10.1099/jgv.0.001068&mimeType=html&fmt=ahah

References

  1. Fooks AR, Cliquet F, Finke S, Freuling C, Hemachudha T et al. Rabies. Nat Rev Dis Primers 2017;3:17091 [CrossRef][PubMed]
    [Google Scholar]
  2. Banyard AC, Fooks AR. The impact of novel lyssavirus discovery. Microbiol Aust 2017;38:18–21
    [Google Scholar]
  3. Hayman DT, Fooks AR, Marston DA, Garcia-R JC. The global phylogeography of lyssaviruses – challenging the 'Out of Africa' hypothesis. PLoS Negl Trop Dis 2016;10:e0005266 [CrossRef][PubMed]
    [Google Scholar]
  4. Badrane H, Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 2001;75:8096–8104 [CrossRef][PubMed]
    [Google Scholar]
  5. Badrane H, Bahloul C, Perrin P, Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001;75:3268–3276 [CrossRef][PubMed]
    [Google Scholar]
  6. Fooks A. The challenge of new and emerging lyssaviruses. Expert Rev Vaccines 2004;3:333–336 [CrossRef][PubMed]
    [Google Scholar]
  7. Kuzmin IV, Hughes GJ, Botvinkin AD, Orciari LA, Rupprecht CE. Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition. Virus Res 2005;111:28–43 [CrossRef]
    [Google Scholar]
  8. Fekadu M, Shaddock JH, Sanderlin DW, Smith JS. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses. Vaccine 1988;6:533–539 [CrossRef][PubMed]
    [Google Scholar]
  9. Brookes SM, Parsons G, Johnson N, Mcelhinney LM, Fooks AR. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 2005;23:4101–4109 [CrossRef][PubMed]
    [Google Scholar]
  10. Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS et al. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 2005;111:44–54 [CrossRef]
    [Google Scholar]
  11. Malerczyk C, Freuling C, Gniel D, Giesen A, Selhorst T et al. Cross-neutralization of antibodies induced by vaccination with purified chick embryo cell vaccine (PCECV) against different Lyssavirus species. Hum Vaccin Immunother 2014;10:2799–2804 [CrossRef]
    [Google Scholar]
  12. King A, Crick J. Rabies-related viruses. In Campbell JB. (editor) Rabies Boston: Kluwer Academic Publishers; 1988; pp.177–200
    [Google Scholar]
  13. Markotter W, van Eeden C, Kuzmin IV, Rupprecht CE, Paweska JT et al. Epidemiology and pathogenicity of African bat lyssaviruses. Dev Biol 2008;131:317–325[PubMed]
    [Google Scholar]
  14. Wright E, Temperton NJ, Marston DA, Mcelhinney LM, Fooks AR et al. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 2008;89:2204–2213 [CrossRef][PubMed]
    [Google Scholar]
  15. Kuzmin IV, Franka R, Rupprecht CE. Experimental infection of big brown bats (Eptesicus fuscus) with West Caucasian bat virus (WCBV). Dev Biol 2008;131:327–337
    [Google Scholar]
  16. Kuzmin IV, Botvinkin AD, Poleschuk EM, Orciari LA, Rupprecht CE. Bat rabies surveillance in the former Soviet Union. Dev Biol 2006;125:273–282[PubMed]
    [Google Scholar]
  17. Horton DL, Banyard AC, Marston DA, Wise E, Selden D et al. Antigenic and genetic characterization of a divergent African virus, Ikoma lyssavirus. J Gen Virol 2014;95:1025–1032 [CrossRef][PubMed]
    [Google Scholar]
  18. Aréchiga Ceballos N, Vázquez Morón S, Berciano JM, Nicolás O, Aznar López C et al. Novel lyssavirus in bat, Spain. Emerg Infect Dis 2013;19:793–795 [CrossRef][PubMed]
    [Google Scholar]
  19. Bahloul C, Jacob Y, Tordo N, Perrin P. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 1998;16:417–425 [CrossRef][PubMed]
    [Google Scholar]
  20. Jallet C, Jacob Y, Bahloul C, Drings A, Desmezieres E et al. Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 1999;73:225–233[PubMed]
    [Google Scholar]
  21. Desmézières E, Jacob Y, Saron MF, Delpeyroux F, Tordo N et al. Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines. J Gen Virol 1999;80:2343–2351 [CrossRef][PubMed]
    [Google Scholar]
  22. Weyer J, Kuzmin IV, Rupprecht CE, Nel LH. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Epidemiol Infect 2008;136:670–678 [CrossRef][PubMed]
    [Google Scholar]
  23. Evans JS, Horton DL, Easton AJ, Fooks AR, Banyard AC. Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?. Vaccine 2012;30:7447–7454 [CrossRef][PubMed]
    [Google Scholar]
  24. Marston DA, Ellis RJ, Wise EL, Aréchiga-Ceballos N, Freuling CM et al. Complete genome sequence of lleida bat lyssavirus. Genome Announc 2017;5:e01427-16 [CrossRef][PubMed]
    [Google Scholar]
  25. Brookes SM, Healy DM, Fooks AR. Ability of rabies vaccine strains to elicit cross-neutralising antibodies. Dev Biol 2006;125:185–193[PubMed]
    [Google Scholar]
  26. Cliquet F, Aubert M, Sagné L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 1998;212:79–87 [CrossRef][PubMed]
    [Google Scholar]
  27. Healy DM, Brookes SM, Banyard AC, Núñez A, Cosby SL et al. Pathobiology of rabies virus and the European bat lyssaviruses in experimentally infected mice. Virus Res 2013;172:46–53 [CrossRef]
    [Google Scholar]
  28. Fahrion AS, Taylor LH, Torres G, Müller T, Dürr S et al. The road to dog rabies control and elimination-what keeps us from moving faster?. Front Public Health 2017;5:103 [CrossRef][PubMed]
    [Google Scholar]
  29. Fooks AR, Mcelhinney LM, Pounder DJ, Finnegan CJ, Mansfield K et al. Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis. J Med Virol 2003;71:281–289 [CrossRef][PubMed]
    [Google Scholar]
  30. van Thiel PP, van den Hoek JA, Eftimov F, Tepaske R, Zaaijer HJ et al. Fatal case of human rabies (Duvenhage virus) from a bat in Kenya: The Netherlands, December 2007. Euro Surveill 2008;13:8007[PubMed]
    [Google Scholar]
  31. Lumio J, Hillbom M, Roine R, Ketonen L, Haltia M et al. Human rabies of bat origin in Europe. Lancet 1986;1:378 [CrossRef][PubMed]
    [Google Scholar]
  32. Gould AR, Hyatt AD, Lunt R, Kattenbelt JA, Hengstberger S et al. Characterisation of a novel lyssavirus isolated from Pteropid bats in Australia. Virus Res 1998;54:165–187 [CrossRef][PubMed]
    [Google Scholar]
  33. Whelan SP, Ball LA, Barr JN, Wertz GT. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 1995;92:8388–8392 [CrossRef][PubMed]
    [Google Scholar]
  34. Rupprecht CR. (editor) Lyssavirus Diversity, Immunological Breath and the Fermi-Paradox Revisited. Rabies Serology Meting 2017; 2017 14th-15th June 2017 Budapest, Hungary:
    [Google Scholar]
  35. Hooper DC, Phares TW, Fabis MJ, Roy A. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis 2009;3:e535 [CrossRef][PubMed]
    [Google Scholar]
  36. Wang ZW, Sarmento L, Wang Y, Li XQ, Dhingra V et al. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 2005;79:12554–12565 [CrossRef][PubMed]
    [Google Scholar]
  37. Banyard AC, Healy DM, Brookes SM, Voller K, Hicks DJ et al. Lyssavirus infection: 'low dose, multiple exposure' in the mouse model. Virus Res 2014;181:35–42 [CrossRef][PubMed]
    [Google Scholar]
  38. Turmelle AS, Jackson FR, Green D, McCracken GF, Rupprecht CE. Host immunity to repeated rabies virus infection in big brown bats. J Gen Virol 2010;91:2360–2366 [CrossRef][PubMed]
    [Google Scholar]
  39. Schatz J, Fooks AR, McElhinney L, Horton D, Echevarria J et al. Bat rabies surveillance in Europe. Zoonoses Public Health 2013;60:22–34 [CrossRef][PubMed]
    [Google Scholar]
  40. Schatz J, Freuling CM, Auer E, Goharriz H, Harbusch C et al. Enhanced passive bat rabies surveillance in indigenous bat species from Germany–a retrospective study. PLoS Negl Trop Dis 2014;8:e2835 [CrossRef]
    [Google Scholar]
  41. Schatz J, Ohlendorf B, Busse P, Pelz G, Dolch D et al. Twenty years of active bat rabies surveillance in Germany: a detailed analysis and future perspectives. Epidemiol Infect 2014;142:1155–1166 [CrossRef][PubMed]
    [Google Scholar]
  42. Wise EL, Marston DA, Banyard AC, Goharriz H, Selden D et al. Passive surveillance of United Kingdom bats for lyssaviruses (2005-2015). Epidemiol Infect 2017;145:2445–2457 [CrossRef][PubMed]
    [Google Scholar]
  43. Eggerbauer E, Troupin C, Passior K, Pfaff F, Höper D et al. The recently discovered Bokeloh Bat Lyssavirus: insights into its genetic heterogeneity and spatial distribution in Europe and the population genetics of its primary host. Adv Virus Res 2017;99:199–232 [CrossRef][PubMed]
    [Google Scholar]
  44. Webster WA. A tissue culture infection test in routine rabies diagnosis. Can J Vet Res 1987;51:367–369[PubMed]
    [Google Scholar]
  45. Aubert M. Methods for the calculation of titres. In Meslin FX, kaplan MM, Koprowski H. Laboratory Techniques in Rabies Geneva: World Health Organisation; 1996; pp.445–459
    [Google Scholar]
  46. Dean DJ, Abelseth MK, Atanasiu P. The fluorescent antibody test. In Meslin FX, kaplan MM, Koprowski H. (editors) Laboratory Techniques in Rabies Geneva: World Health Organisation; 1996; pp.88–93
    [Google Scholar]
  47. Schneider LG, Barnard BJH, Schneider HP. Application of monoclonal antibodies for epidemiological investigations and oral vaccination studies: I- African viruses. In Kuwert CM, Koprowski H, Bogel K. Rabies in the Tropics Berlin: Springer-Verlag; 1985; pp.49–53
    [Google Scholar]
  48. Orbanz J, Finke S. Generation of recombinant European bat lyssavirus type 1 and inter-genotypic compatibility of lyssavirus genotype 1 and 5 antigenome promoters. Arch Virol 2010;155:1631–1641 [CrossRef][PubMed]
    [Google Scholar]
  49. Hicks DJ, Núñez A, Banyard AC, Williams A, Ortiz-Pelaez A et al. Differential chemokine responses in the murine brain following lyssavirus infection. J Comp Pathol 2013;149:446–462 [CrossRef][PubMed]
    [Google Scholar]
  50. Heaton PR, Johnstone P, McElhinney LM, Cowley R, O'Sullivan E et al. Heminested PCR assay for detection of six genotypes of rabies and rabies-related viruses. J Clin Microbiol 1997;35:2762–2766[PubMed]
    [Google Scholar]
  51. Freuling CM, McElhinney LM, Fooks AR, Müller TF. Gel-based reverse transcription-polymerase chain reaction. In Current Laboratory Techniques in Rabies Diagnosis, Research and Preventionvol. 2 San Diego and London: Academic Press; 2015; pp.119–128
    [Google Scholar]
  52. Hayman DT, Banyard AC, Wakeley PR, Harkess G, Marston D et al. A universal real-time assay for the detection of Lyssaviruses. J Virol Methods 2011;177:87–93 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001068
Loading
/content/journal/jgv/10.1099/jgv.0.001068
Loading

Data & Media loading...

Supplements

Supplementary File 2

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error